{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T05:14:02Z","timestamp":1760850842118,"version":"build-2065373602"},"reference-count":20,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["20ck0106567s0201"],"award-info":[{"award-number":["20ck0106567s0201"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Nuclear Medicine and Biology"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1016\/j.nucmedbio.2022.02.001","type":"journal-article","created":{"date-parts":[[2022,2,8]],"date-time":"2022-02-08T02:07:37Z","timestamp":1644286057000},"page":"10-15","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Identification and quantitative structure\u2013activity relationship assessment of trace chemical impurities contained in the therapeutic formulation of [64Cu]Cu-ATSM"],"prefix":"10.1016","volume":"108-109","author":[{"given":"Chika","family":"Igarashi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroki","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masashi","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fukiko","family":"Hihara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoko","family":"Tachibana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ming-Rong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroaki","family":"Kurihara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatsuya","family":"Higashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yukie","family":"Yoshii","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.nucmedbio.2022.02.001_bb0005","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0023945","article-title":"NADPH oxidase subunit 4-mediated reactive oxygen species contribute to cycling hypoxia-promoted tumor progression in glioblastoma multiforme","volume":"6","author":"Hsieh","year":"2011","journal-title":"PLOS ONE"},{"key":"10.1016\/j.nucmedbio.2022.02.001_bb0010","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1097\/00005072-200606000-00001","article-title":"\u201cPseudopalisading\u201d necrosis in glioblastoma: a familiar morphologic feature that links vascular pathology, hypoxia, and angiogenesis","volume":"65","author":"Rong","year":"2006","journal-title":"J Neuropathol Exp Neurol"},{"key":"10.1016\/j.nucmedbio.2022.02.001_bb0015","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.bcp.2006.03.020","article-title":"Adenosine modulates vascular endothelial growth factor expression via hypoxia-inducible factor-1 in human glioblastoma cells","volume":"72","author":"Merighi","year":"2006","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.nucmedbio.2022.02.001_bb0020","doi-asserted-by":"crossref","first-page":"2332","DOI":"10.1158\/1055-9965.EPI-06-0369","article-title":"Hypoxia-inducible factor 1 as a possible target for cancer chemoprevention","volume":"15","author":"L\u00f3pez-L\u00e1zaro","year":"2006","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.nucmedbio.2022.02.001_bb0025","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.3892\/ol.2016.4952","article-title":"Glioblastoma multiforme: effect of hypoxia and hypoxia inducible factors on therapeutic approaches","volume":"12","author":"Huang","year":"2016","journal-title":"Oncol Lett"},{"key":"10.1016\/j.nucmedbio.2022.02.001_bb0030","first-page":"5863","article-title":"The hypoxic cell: a target for selective cancer therapy\u2013eighteenth Bruce F.Cain Memorial Award lecture","volume":"59","author":"Brown","year":"1999","journal-title":"Cancer Res"},{"key":"10.1016\/j.nucmedbio.2022.02.001_bb0035","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/BF02988690","article-title":"Evaluation of 62Cu labeled diacetyl-bis(N4-methylthiosemicarbazone) as a hypoxic tissue tracer in patients with lung cancer","volume":"14","author":"Takahashi","year":"2000","journal-title":"Ann Nucl Med"},{"key":"10.1016\/j.nucmedbio.2022.02.001_bb0040","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.2967\/jnumed.108.051326","article-title":"An imaging comparison of 64Cu-ATSM and 60Cu-ATSM in cancer of the uterine cervix","volume":"49","author":"Lewis","year":"2008","journal-title":"J Nucl Med"},{"key":"10.1016\/j.nucmedbio.2022.02.001_bb0045","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.1021\/ic401607z","article-title":"Underscoring the influence of inorganic chemistry on nuclear imaging with radiometals","volume":"53","author":"Zeglis","year":"2014","journal-title":"Inorg Chem"},{"key":"10.1016\/j.nucmedbio.2022.02.001_bb0050","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.nucmedbio.2009.11.004","article-title":"Some thoughts on the mechanism of cellular trapping of Cu(II)-ATSM","volume":"37","author":"Dearling","year":"2010","journal-title":"Nucl Med Biol"},{"key":"10.1016\/j.nucmedbio.2022.02.001_bb0055","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1007\/BF02988502","article-title":"Retention mechanism of hypoxia selective nuclear imaging\/radiotherapeutic agent Cu-diacetyl-bis(N4-methylthiosemicarbazone) (Cu-ATSM) in tumor cells","volume":"15","author":"Obata","year":"2001","journal-title":"Ann Nucl Med"},{"key":"10.1016\/j.nucmedbio.2022.02.001_bb0060","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1088\/0031-9155\/54\/7\/017","article-title":"In vitro kinetic studies on the mechanism of oxygen-dependent cellular uptake of copper radiopharmaceuticals","volume":"54","author":"Holland","year":"2009","journal-title":"Phys Med Biol"},{"key":"10.1016\/j.nucmedbio.2022.02.001_bb0065","first-page":"177","article-title":"Evaluation of 64Cu-ATSM in vitro and in vivo in a hypoxic tumor model","volume":"40","author":"Lewis","year":"1999","journal-title":"J Nucl Med"},{"key":"10.1016\/j.nucmedbio.2022.02.001_bb0070","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1021\/jm0104217","article-title":"Studies on the mechanism of hypoxic selectivity in copper bis(thiosemicarbazone) radiopharmaceuticals","volume":"45","author":"Maurer","year":"2002","journal-title":"J Med Chem"},{"key":"10.1016\/j.nucmedbio.2022.02.001_bb0075","first-page":"379","article-title":"Copper-64 radiopharmaceuticals for PET imaging of cancer: advances in preclinical and clinical research","volume":"24","author":"Anderson","year":"2009","journal-title":"Cancer Biother Radiopharm"},{"key":"10.1016\/j.nucmedbio.2022.02.001_bb0080","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1093\/jrr\/rrv042","article-title":"Validation of 64Cu-ATSM damaging DNA via high-LET Auger electron emission","volume":"56","author":"McMillan","year":"2015","journal-title":"J Radiat Res"},{"key":"10.1016\/j.nucmedbio.2022.02.001_bb0085","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.tranon.2017.10.006","article-title":"Multiple administrations of 64Cu-ATSM as a novel therapeutic option for glioblastoma: a tanslational study using mice with xenografts","volume":"11","author":"Yoshii","year":"2018","journal-title":"Transl Oncol"},{"key":"10.1016\/j.nucmedbio.2022.02.001_bb0090","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1007\/s10967-019-06738-9","article-title":"Process development of [64Cu]Cu-ATSM: efficient stabilization and sterilization for therapeutic applications","volume":"322","author":"Matsumoto","year":"2019","journal-title":"J Radioanal Nucl Chem"},{"key":"10.1016\/j.nucmedbio.2022.02.001_bb0095","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1016\/j.tranon.2019.05.017","article-title":"Preclinical pharmacokinetic and safety studies of copper-diacetyl-bis(N4-Methylthiosemicarbazone) (Cu-ATSM): translational studies for internal radiotherapy","volume":"12","author":"Matsumoto","year":"2019","journal-title":"Transl Oncol"},{"key":"10.1016\/j.nucmedbio.2022.02.001_bb0100","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1080\/1062936X.2015.1136680","article-title":"QSAR toolbox - workflow and major functionalities","volume":"27","author":"Dimitrov","year":"2016","journal-title":"SAR QSAR Environ Res"}],"container-title":["Nuclear Medicine and Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0969805122000129?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0969805122000129?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T04:30:08Z","timestamp":1760848208000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0969805122000129"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":20,"alternative-id":["S0969805122000129"],"URL":"https:\/\/doi.org\/10.1016\/j.nucmedbio.2022.02.001","relation":{},"ISSN":["0969-8051"],"issn-type":[{"type":"print","value":"0969-8051"}],"subject":[],"published":{"date-parts":[[2022,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Identification and quantitative structure\u2013activity relationship assessment of trace chemical impurities contained in the therapeutic formulation of [64Cu]Cu-ATSM","name":"articletitle","label":"Article Title"},{"value":"Nuclear Medicine and Biology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nucmedbio.2022.02.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}